202 related articles for article (PubMed ID: 17466519)
21. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor.
Marriott KS; Huffman JW; Wiley JL; Martin BR
Bioorg Med Chem; 2006 Apr; 14(7):2386-97. PubMed ID: 16321538
[TBL] [Abstract][Full Text] [Related]
23. Discovery of a novel class of selective human CB1 inverse agonists.
Foloppe N; Allen NH; Bentley CH; Brooks TD; Kennett G; Knight AR; Leonardi S; Misra A; Monck NJ; Sellwood DM
Bioorg Med Chem Lett; 2008 Feb; 18(3):1199-206. PubMed ID: 18083560
[TBL] [Abstract][Full Text] [Related]
24. A new class of histamine H3 receptor antagonists derived from ligand based design.
Roche O; Rodríguez Sarmiento RM
Bioorg Med Chem Lett; 2007 Jul; 17(13):3670-5. PubMed ID: 17498953
[TBL] [Abstract][Full Text] [Related]
25. Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern.
Lange JH; van der Neut MA; Borst AJ; Yildirim M; van Stuivenberg HH; van Vliet BJ; Kruse CG
Bioorg Med Chem Lett; 2010 May; 20(9):2770-5. PubMed ID: 20363132
[TBL] [Abstract][Full Text] [Related]
26. The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
Durdagi S; Kapou A; Kourouli T; Andreou T; Nikas SP; Nahmias VR; Papahatjis DP; Papadopoulos MG; Mavromoustakos T
J Med Chem; 2007 Jun; 50(12):2875-85. PubMed ID: 17521177
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
Manera C; Benetti V; Castelli MP; Cavallini T; Lazzarotti S; Pibiri F; Saccomanni G; Tuccinardi T; Vannacci A; Martinelli A; Ferrarini PL
J Med Chem; 2006 Oct; 49(20):5947-57. PubMed ID: 17004710
[TBL] [Abstract][Full Text] [Related]
28. Biaryl cannabinoid mimetics--synthesis and structure-activity relationship.
Worm K; Zhou QJ; Stabley GJ; DeHaven RN; Dolle RE
Bioorg Med Chem Lett; 2007 Jul; 17(13):3652-6. PubMed ID: 17507224
[TBL] [Abstract][Full Text] [Related]
29. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
Diaz P; Phatak SS; Xu J; Astruc-Diaz F; Cavasotto CN; Naguib M
J Med Chem; 2009 Jan; 52(2):433-44. PubMed ID: 19115816
[TBL] [Abstract][Full Text] [Related]
30. 5-Sulfonyl-benzimidazoles as selective CB2 agonists.
Verbist BM; De Cleyn MA; Surkyn M; Fraiponts E; Aerssens J; Nijsen MJ; Gijsen HJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2574-9. PubMed ID: 18394887
[TBL] [Abstract][Full Text] [Related]
31. Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.
Ermann M; Riether D; Walker ER; Mushi IF; Jenkins JE; Noya-Marino B; Brewer ML; Taylor MG; Amouzegh P; East SP; Dymock BW; Gemkow MJ; Kahrs AF; Ebneth A; Löbbe S; O'Shea K; Shih DT; Thomson D
Bioorg Med Chem Lett; 2008 Mar; 18(5):1725-9. PubMed ID: 18255291
[TBL] [Abstract][Full Text] [Related]
32. Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
De Freitas GB; da Silva LL; Romeiro NC; Fraga CA
Eur J Med Chem; 2009 Jun; 44(6):2482-96. PubMed ID: 19249138
[TBL] [Abstract][Full Text] [Related]
33. The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives.
Omura H; Kawai M; Shima A; Iwata Y; Ito F; Masuda T; Ohta A; Makita N; Omoto K; Sugimoto H; Kikuchi A; Iwata H; Ando K
Bioorg Med Chem Lett; 2008 Jun; 18(11):3310-4. PubMed ID: 18440813
[TBL] [Abstract][Full Text] [Related]
34. New 1,2,3,4-tetrahydropyrrolo[3,4-b]indole derivatives as selective CB2 receptor agonists.
Pagé D; Yang H; Brown W; Walpole C; Fleurent M; Fyfe M; Gaudreault F; St-Onge S
Bioorg Med Chem Lett; 2007 Nov; 17(22):6183-7. PubMed ID: 17884494
[TBL] [Abstract][Full Text] [Related]
35. Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic properties.
Marx IE; DiMauro EF; Cheng A; Emkey R; Hitchcock SA; Huang L; Huang MY; Human J; Lee JH; Li X; Martin MW; White RD; Fremeau RT; Patel VF
Bioorg Med Chem Lett; 2009 Jan; 19(1):31-5. PubMed ID: 19062274
[TBL] [Abstract][Full Text] [Related]
36. N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
Ohta H; Ishizaka T; Tatsuzuki M; Yoshinaga M; Iida I; Tomishima Y; Toda Y; Saito S
Bioorg Med Chem Lett; 2007 Nov; 17(22):6299-304. PubMed ID: 17884496
[TBL] [Abstract][Full Text] [Related]
37. Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
Foloppe N; Benwell K; Brooks TD; Kennett G; Knight AR; Misra A; Monck NJ
Bioorg Med Chem Lett; 2009 Aug; 19(15):4183-90. PubMed ID: 19520572
[TBL] [Abstract][Full Text] [Related]
38. Discovery and optimization of novel purines as potent and selective CB2 agonists.
Hollinshead SP; Astles PC; Chambers MG; Johnson MP; Palmer J; Tidwell MW
Bioorg Med Chem Lett; 2012 Aug; 22(15):4962-6. PubMed ID: 22765893
[TBL] [Abstract][Full Text] [Related]
39. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor.
Salo OM; Raitio KH; Savinainen JR; Nevalainen T; Lahtela-Kakkonen M; Laitinen JT; Järvinen T; Poso A
J Med Chem; 2005 Nov; 48(23):7166-71. PubMed ID: 16279774
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.
Pettersson H; Bülow A; Ek F; Jensen J; Ottesen LK; Fejzic A; Ma JN; Del Tredici AL; Currier EA; Gardell LR; Tabatabaei A; Craig D; McFarland K; Ott TR; Piu F; Burstein ES; Olsson R
J Med Chem; 2009 Apr; 52(7):1975-82. PubMed ID: 19338356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
